GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM

How do these treatments for type 2 diabetes compare in terms of cardiovascular and renal outcomes and risk for adverse events?Journal of the Endocrine Society

Source: Medscape Today Headlines - June 16, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news